Routes of
administration By mouth Protein binding 93,9% Biological half-life 7.3–12.1 hours | ATC code G04BE11 (WHO) Metabolism Molar mass 516.657 g/mol | |
 | ||
Legal status US: Not FDA approved
In general: ℞ (Prescription only) | ||
Udenafil industry analysis for global and china regions 2009 2019
The drug udenafil, marketed under the trade name Zydena, is within the PDE5 inhibitor class (which also includes avanafil, sildenafil, tadalafil, and vardenafil). Used, like other PDE5 inhibitors, to treat erectile dysfunction, udenafil was developed by Dong-A Pharmaceutical. With action of fairly rapid onset (peak plasma concentration after 1 to 1.5 hours) yet long duration (plasma half life of 11 to 13 hours), udenafil's pharmacokinetics allows once-daily dosage (in addition to on-demand use). Typical doses are 100 and 200 mg. Udenafil is available in Korea, Russia, and the Philippines; in the United States, it has not been approved by the U.S. Food and Drug Administration.
References
Udenafil Wikipedia(Text) CC BY-SA